-
2
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
3
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
4
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer
-
Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
5
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
7
-
-
85024133429
-
-
https://online.epocrates.com/noFrame/show Page.do?method-drugs&MonographId-3619&Active SectionId-10
-
-
-
-
8
-
-
77954651388
-
Uncertainty in assessing value of oncology treatments
-
Mullins CD, Montgomery R, Tunis S: Uncertainty in assessing value of oncology treatments. Oncologist 15:58-64, 2010 (suppl 1)
-
(2010)
Oncologist
, vol.15
, pp. 58-64
-
-
Mullins, C.D.1
Montgomery, R.2
Tunis, S.3
-
9
-
-
0027645744
-
Potential for cancer related health services research using a linked Medicare-tumor registry database
-
Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
-
(1993)
Med Care
, vol.31
, pp. 732-748
-
-
Potosky, A.L.1
Riley, G.F.2
Lubitz, J.D.3
-
10
-
-
0004299806
-
-
(9th revision). Geneva, Switzerland
-
World Health Organization: International Classification of Disease (9th revision). Geneva, Switzerland, 2008
-
(2008)
International Classification of Disease
-
-
-
11
-
-
71549137792
-
Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer
-
Hershman DL, Buono DL, Malin J, et al: Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 101:1633-1641, 2009
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 1633-1641
-
-
Hershman, D.L.1
Buono, D.L.2
Malin, J.3
-
12
-
-
34547136178
-
Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer
-
Du XL, Fang S, Vernon SW, et al: Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660-669, 2007
-
(2007)
Cancer
, vol.110
, pp. 660-669
-
-
Du, X.L.1
Fang, S.2
Vernon, S.W.3
-
13
-
-
0022474696
-
Assessing illness severity: Does clinical judgment work?
-
Charlson ME, Sax FL, MacKenzie CR, et al: Assessing illness severity: Does clinical judgment work? J Chronic Dis 39:439-452, 1986
-
(1986)
J Chronic Dis
, vol.39
, pp. 439-452
-
-
Charlson, M.E.1
Sax, F.L.2
MacKenzie, C.R.3
-
14
-
-
0034531923
-
Development of a comorbidity index using physician claims data
-
Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
-
(2000)
J Clin Epidemiol
, vol.53
, pp. 1258-1267
-
-
Klabunde, C.N.1
Potosky, A.L.2
Legler, J.M.3
-
15
-
-
17144465669
-
Measuring complications of cancer treatment using the SEER-Medicare data
-
Potosky AL, Warren JL, Riedel ER, et al: Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV-62-8, 2002
-
(2002)
Med Care
, vol.40
, pp. IV-8
-
-
Potosky, A.L.1
Warren, J.L.2
Riedel, E.R.3
-
16
-
-
33644898103
-
Increasing trial generalizability
-
Gotay CC: Increasing trial generalizability. J Clin Oncol 24:846-847, 2006
-
(2006)
J Clin Oncol
, vol.24
, pp. 846-847
-
-
Gotay, C.C.1
-
17
-
-
80054818006
-
Outcomes when cancer treatment is delivered on, or off, a clinical trial: Implications for generalizability of study results
-
Markman M: Outcomes when cancer treatment is delivered on, or off, a clinical trial: Implications for generalizability of study results. Oncology 81:141-142, 2011
-
(2011)
Oncology
, vol.81
, pp. 141-142
-
-
Markman, M.1
-
18
-
-
80052286823
-
Cancer trials versus the real world in the United States
-
discussion 42-43
-
Al-Refaie WB, Vickers SM, Zhong W, et al: Cancer trials versus the real world in the United States. Ann Surg 254:438-442, 2011; discussion 42-43
-
(2011)
Ann Surg
, vol.254
, pp. 438-442
-
-
Al-Refaie, W.B.1
Vickers, S.M.2
Zhong, W.3
-
19
-
-
0038257702
-
-
Subtitle B
-
NIH Revitalization Act. Subtitle B:131-133. 1993
-
(1993)
NIH Revitalization Act
, pp. 131-133
-
-
-
20
-
-
33644847203
-
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials
-
Unger JM, Coltman CA Jr, Crowley JJ, et al: Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 24:141-144, 2006
-
(2006)
J Clin Oncol
, vol.24
, pp. 141-144
-
-
Unger, J.M.1
Coltman, C.A.2
Crowley, J.J.3
-
21
-
-
2642573558
-
Participation in cancer clinical trials: Race-, sex-, and agebased disparities
-
Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: Race-, sex-, and agebased disparities. JAMA 291:2720-2726, 2004
-
(2004)
JAMA
, vol.291
, pp. 2720-2726
-
-
Murthy, V.H.1
Krumholz, H.M.2
Gross, C.P.3
-
22
-
-
84858843113
-
Uptake and economic impact of first-cycle colonystimulating factor use during adjuvant treatment of breast cancer
-
Hershman DL, Wilde ET, Wright JD, et al: Uptake and economic impact of first-cycle colonystimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 30:806-812, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 806-812
-
-
Hershman, D.L.1
Wilde, E.T.2
Wright, J.D.3
-
23
-
-
80052712426
-
Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer
-
Wright JD, Neugut AI, Wilde ET, et al: Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol 29:3408-3418, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 3408-3418
-
-
Wright, J.D.1
Neugut, A.I.2
Wilde, E.T.3
-
24
-
-
84864283129
-
Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience
-
Lerose R, Musto P, Aieta M, et al: Off-label use of anti-cancer drugs between clinical practice and research: The Italian experience. Eur J Clin Pharmacol 68:505-512, 2012
-
(2012)
Eur J Clin Pharmacol
, vol.68
, pp. 505-512
-
-
Lerose, R.1
Musto, P.2
Aieta, M.3
-
25
-
-
71549119500
-
Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention
-
Tsai TT, Maddox TM, Roe MT, et al: Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 302:2458-2464, 2009
-
(2009)
JAMA
, vol.302
, pp. 2458-2464
-
-
Tsai, T.T.1
Maddox, T.M.2
Roe, M.T.3
-
26
-
-
67649776649
-
Racial differences in definitive breast cancer therapy in older women: Are they explained by the hospitals where patients undergo surgery?
-
Keating NL, Kouri E, He Y, et al: Racial differences in definitive breast cancer therapy in older women: Are they explained by the hospitals where patients undergo surgery? Med Care 47:765-773, 2009
-
(2009)
Med Care
, vol.47
, pp. 765-773
-
-
Keating, N.L.1
Kouri, E.2
He, Y.3
-
27
-
-
78650702699
-
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care
-
Freedman RA, Virgo KS, He Y, et al: The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 117:180-189, 2011
-
(2011)
Cancer
, vol.117
, pp. 180-189
-
-
Freedman, R.A.1
Virgo, K.S.2
He, Y.3
-
28
-
-
0025327310
-
Black-white disparities in health care
-
Black-white disparities in health care. JAMA 263:2344-2346, 1990
-
(1990)
JAMA
, vol.263
, pp. 2344-2346
-
-
-
29
-
-
53049099678
-
Bevacizumab in advanced cancer, too much or too little?
-
Jirillo A, Vascon F, Giacobbo M: Bevacizumab in advanced cancer, too much or too little? Ann Oncol 19:1817-1818, 2008
-
(2008)
Ann Oncol
, vol.19
, pp. 1817-1818
-
-
Jirillo, A.1
Vascon, F.2
Giacobbo, M.3
-
30
-
-
84861309946
-
The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy
-
Dawood S, Shaikh AJ, Buchholz TA, et al: The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 118:2780-2786, 2012
-
(2012)
Cancer
, vol.118
, pp. 2780-2786
-
-
Dawood, S.1
Shaikh, A.J.2
Buchholz, T.A.3
-
31
-
-
20644432867
-
Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
-
Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 3502-3508
-
-
Hurwitz, H.I.1
Fehrenbacher, L.2
Hainsworth, J.D.3
-
32
-
-
30444449389
-
Reform of drug regulation-beyond an independent drug-safety board
-
Ray WA, Stein CM: Reform of drug regulation-Beyond an independent drug-safety board. N Engl J Med 354:194-201, 2006
-
(2006)
N Engl J Med
, vol.354
, pp. 194-201
-
-
Ray, W.A.1
Stein, C.M.2
-
33
-
-
0038478965
-
Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population
-
Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18, 2002
-
(2002)
Med Care
, vol.40
, pp. IV-18
-
-
Warren, J.L.1
Klabunde, C.N.2
Schrag, D.3
-
34
-
-
55549114347
-
Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy
-
Smith GL, Smith BD, Buchholz TA, et al: Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 26:5119-5125, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 5119-5125
-
-
Smith, G.L.1
Smith, B.D.2
Buchholz, T.A.3
-
35
-
-
33745839859
-
Late gastrointestinal toxicity after radiation for prostate cancer
-
Giordano SH, Lee A, Kuo YF, et al: Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 107:423-432, 2006
-
(2006)
Cancer
, vol.107
, pp. 423-432
-
-
Giordano, S.H.1
Lee, A.2
Kuo, Y.F.3
-
36
-
-
33747400905
-
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer
-
Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 1108-1117
-
-
Hassett, M.J.1
O'Malley, A.J.2
Pakes, J.R.3
|